Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2

Area of Science:

• Ophthalmology
• Pharmacology
• Allergy & Immunology

Background:

• Olopatadine is an antihistamine and mast cell stabilizer for allergic conjunctivitis.
• Olopatadine 0.7% is a recently approved, higher-strength daily dosing formulation in the US, replacing the 0.2% strength.
• Understanding patient response to different olopatadine strengths is crucial for optimizing treatment.

Purpose of the Study:

• To characterize patients experiencing superior 24-hour itching relief with olopatadine 0.7% versus 0.2%.
• To correlate this improved relief with baseline itching severity as a proxy for antihistamine sensitivity.
• To model and predict ocular itching scores and treatment response differences.

Main Methods:

• Retrospective analysis of data from two conjunctival allergen challenge (CAC) studies.
• Development of a differential odds model to characterize individual and population-level responses.
• Utilized a one-compartment kinetic-pharmacodynamic Emax model to assess olopatadine's effect, incorporating baseline severity, vehicle, and drug effects.

Main Results:

• The developed model accurately quantified observed trends in clinical data for mean scores and response proportions.
• Model predictions indicated a higher proportion of patients achieving 24-hour relief with olopatadine 0.7% compared to 0.2%.
• Retrospective data analysis confirmed these predictions, showing increased relief with 0.7% olopatadine in patients with moderate-to-high baseline itching.

Conclusions:

• Olopatadine 0.7% demonstrates superior 24-hour ocular itching relief compared to olopatadine 0.2% for allergic conjunctivitis.
• The benefit of olopatadine 0.7% is more pronounced in patients with higher baseline itching severity.
• This supports the efficacy of the higher concentration for patients requiring more robust antihistamine response.